

VASCADE MVP® XL Venous Vascular Closure System

EXPAND Your PFA & LAAC Closure Capability

The Only Extravascular Venous Closure System Clinically Proven in EP Procedures Using 17F OD Procedural Sheaths¹

VASCADE MVP XL SYSTEM NOW INDICATED FOR
venous vascular closure in 10-14F ID/17F max OD sheaths

25F
diameter disc



19mg
collagen

Approved for
FARADrive™
Steerable Sheath

WATCHMAN TruSteer™
Access System

Agilis NxT Steerable
Introducer, Dual-Reach™

0%

Major & Minor
Complications^{1††}

HAEMONETICS®

The AMBULATE EXPAND Trial

Summary

Prospective, single arm pivotal trial at 8 U.S. centers to evaluate femoral venotomy after catheter-based procedures using 10-14F ID/17F max OD sheaths.

Demonstrated safety and efficacy of the VASCADE MVP® XL venous vascular closure system in 77 patients as follows:¹

- 0% major complications[†]
- 0% minor complications[†]
- Median 2.4 hours time to ambulation (TTA)[‡]
- Median 2.3 minutes time to hemostasis (TTH)
- Median 2.7 hours time to discharge eligibility (TTDE)

Success

The study demonstrated 100% procedure success and device success of 98.7%.¹

Sheath Type by Access Site

Procedural Sheath (OD) Detail	Study Access Sites (N=77)	
	n	%
FARADRIVE™ Steerable Sheath (13F ID/17F OD)	64	83.1%
WATCHMAN TruSteer™ Access System (12F ID/17 OD)	11	14.3%
Agilis NxT Steerable Introducer Dual-Reach™ (13F ID/17F OD)	2	2.6%

Expanded Closure Capability
in EP Procedures using 10-14F ID/17F max OD sheaths



Workflow Wins with A Direct Close


With VASCADE MVP XL system, there is no need to downsize your procedural sheath to a smaller size for closure, which adds time to the procedure while waiting for the vein to recoil.

Designed to close 10-14F ID/17F OD venous access sites following pulsed field ablation (PFA) and left atrial appendage closure (LAAC) procedures, VASCADE MVP XL expands your closure capability.

Built on the Legacy of VASCADE MVP® System

Patients First^{2S}


- Median 2.2 hours time to ambulation – 64% reduction
- 63% improvement in patient satisfaction
- 58% reduction in opioid use post procedure
- 51% reduction in pain medication use post procedure



VASCADE MVP® XL Venous Vascular Closure System

Simply Bigger.

- 25F diameter disc
- 58% more collagen[†]
- Resorbable and thrombogenic collagen plug
- Simple and easy to use
- No sutures, nothing permanent left behind



Features	VASCADE MVP® Venous Vascular Closure System	VASCADE MVP® XL Venous Vascular Closure System	Increase
Collagen	12mg ± 3mg	19mg ± 3mg	58%
Disc Size	23F	25F	9%
Sheath Size Compatibility	6-12 ID (15F maximum OD)	10-14 ID (17F maximum OD)	+2F max OD



Scan to learn more about VASCADE MVP XL

Ordering Information

Product	Catalog Number	Sheath Compatibility	Order Quantity	For Use In
VASCADE MVP XL Venous Vascular Closure System	800-1012XL-10U	10-14F Inner Diameter (17F maximum outer diameter)	1 Box (10 devices per box)	Venous

Please consult product labels, and instructions for use for indications, contraindications, warnings, precautions and adverse events. See VASCADE MVP XL IFU 4911 and VASCADE MVP IFU 3972. For a list of worldwide office locations and contact information, visit www.haemonetics.com/officelocations

* Major venous access site closure-related complications through 30-day follow up

† Minor venous access site closure-related complications through 30-day follow up

‡ In Per Protocol population (N=66)

§ VASCADE MVP System was compared to manual compression.

¶ Compared to VASCADE MVP System

1. VASCADE MVP XL IFU 4911

2. Natale A, et al. Venous vascular closure system versus manual compression following multiple access electrophysiology procedures: The AMBULATE Trial. *JACC Clin Electrophysiol* October 2019. DOI: 10.1016/j.jacep.2019.08.013

3. Al-Ahmad A, et al. Results from the prospective, multicenter AMBULATE-CAP trial: Reduced use of urinary catheters and protamine with hemostasis via the mid-bore venous vascular closure system (Vascade MVP) following multi-access cardiac ablation procedures. *J Cardiovasc Electrophysiol* Dec 2020. <https://doi.org/10.1111/jce.14828>. NCT03573206

4. AMBULATE Same Day Discharge Registry Retrospective Study: NCT04538781

5-6. Eldadah ZA, et al. Same-day discharge following catheter ablation and venous closure with VASCADE MVP: A post-market registry. *J Cardiovasc Electrophysiol* 2022. <https://doi.org/10.1111/jce.15763> NCT04203329

www.haemonetics.com

800-537-2802

© 2026 Haemonetics Corporation. Haemonetics, VASCADE and VASCADE MVP are trademarks or registered trademarks of Haemonetics Corporation in the U.S., other countries or both. All other product names, trademarks and registered trademarks are the property of their respective owners. 03.2026 USA.COL-COPY-002736-US(AA)

HAEMONETICS®